Yuichiro Maekawa Selected Research

romurtide

10/2004

Effect of granulocyte-macrophage colony-stimulating factor inducer on left ventricular remodeling after acute myocardial infarction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuichiro Maekawa Research Topics

Disease

23	Heart Failure 08/2022 - 01/2004
23	Myocardial Infarction 10/2020 - 01/2003
9	Acute Coronary Syndrome 01/2020 - 11/2011
9	Fibrosis (Cirrhosis) 08/2019 - 10/2004
8	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 09/2012
8	Ventricular Remodeling 08/2019 - 04/2003
7	ST Elevation Myocardial Infarction 01/2020 - 11/2009
6	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 04/2022 - 01/2016
6	Thrombosis (Thrombus) 12/2021 - 02/2004
6	Infarction (Infarctions) 06/2017 - 01/2003
5	Hemorrhage 01/2020 - 10/2013
5	Hypertension (High Blood Pressure) 01/2019 - 02/2011
5	Cardiovascular Diseases (Cardiovascular Disease) 06/2016 - 05/2010
4	Hypertrophy 03/2022 - 08/2007
4	Atrial Fibrillation 01/2022 - 06/2020
4	Unstable Angina 10/2020 - 09/2002
4	Ischemia 11/2018 - 11/2013
4	Inflammation (Inflammations) 08/2011 - 03/2008
4	Heart Rupture 12/2010 - 01/2003
3	Atherosclerosis 07/2022 - 08/2016
3	Cardiomegaly (Heart Hypertrophy) 03/2022 - 03/2008
3	Insulin Resistance 07/2019 - 01/2011
3	Aneurysm (Aneurysms) 01/2018 - 07/2011
3	Pulmonary Hypertension 09/2017 - 04/2015
3	Shock 12/2016 - 01/2015
3	Acute Kidney Injury (Acute Renal Failure) 04/2016 - 10/2013
3	Aortic Dissection 02/2015 - 06/2005
3	Abdominal Aortic Aneurysm 10/2011 - 07/2011
3	Necrosis 08/2011 - 02/2009
3	Obesity 08/2011 - 08/2007
3	Death (Near-Death Experience) 12/2010 - 02/2009
2	Rheumatoid Arthritis 03/2022 - 03/2019
2	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 03/2022 - 01/2018
2	Left Ventricular Dysfunction 03/2022 - 12/2010
2	Left Ventricular Outflow Obstruction 01/2022 - 01/2018
2	Pulmonary Embolism 12/2021 - 11/2010
2	Ventricular Fibrillation 10/2021 - 11/2009
2	Myocardial Ischemia (Ischemic Heart Diseases) 01/2020 - 08/2011
2	Reperfusion Injury 01/2019 - 10/2012
2	Heart Arrest (Cardiac Arrest) 01/2017 - 10/2012
2	Hypoxia (Hypoxemia) 01/2017 - 04/2009
2	Ventricular Tachycardia 12/2016 - 11/2009
2	Mitral Valve Insufficiency (Mitral Regurgitation) 01/2016 - 01/2007
2	Aortic Valve Stenosis (Aortic Stenosis) 05/2014 - 09/2012
1	Hypercholesterolemia 07/2022
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2022
1	Amyloid Plaque 03/2022
1	Wounds and Injuries (Trauma) 01/2022

Drug/Important Bio-Agent (IBA)

14	C-Reactive ProteinIBA 02/2019 - 01/2003
6	Pharmaceutical PreparationsIBA 01/2022 - 01/2016
5	CytokinesIBA 03/2012 - 04/2003
5	Messenger RNA (mRNA)IBA 08/2011 - 10/2004
3	Tolvaptan FDA Link 08/2022 - 01/2019
3	omega-Chloroacetophenone (Mace)IBA 10/2020 - 05/2010
3	Glucose (Dextrose)FDA LinkGeneric 07/2019 - 01/2011
3	Brain Natriuretic Peptide (Natrecor)FDA Link 02/2019 - 05/2010
3	Proteins (Proteins, Gene)FDA Link 01/2018 - 02/2009
3	Biomarkers (Surrogate Marker)IBA 01/2014 - 08/2011
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2012 - 01/2011
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 08/2011 - 10/2008
2	Cytochrome P-450 CYP3AIBA 08/2022 - 04/2020
2	CholesterolIBA 07/2022 - 08/2016
2	AA amyloidosisIBA 03/2022 - 05/2014
2	tocilizumab (atlizumab)FDA Link 03/2022 - 05/2014
2	Amyloid (Amyloid Fibrils)IBA 03/2022 - 08/2011
2	Creatine Kinase (Creatine Phosphokinase)IBA 10/2021 - 02/2019
2	Everolimus FDA Link 10/2020 - 08/2016
2	Clopidogrel (Plavix)FDA Link 01/2020 - 06/2016
2	CatecholaminesIBA 02/2019 - 12/2016
2	Mitochondrial Permeability Transition PoreIBA 11/2018 - 12/2017
2	Phosphotransferases (Kinase)IBA 01/2018 - 12/2017
2	Oxygen (Dioxygen)IBA 06/2017 - 01/2017
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2017 - 08/2016
2	Trinitrotoluene (TNT)IBA 01/2017 - 01/2014
2	Biological ProductsIBA 10/2012 - 04/2009
2	EnzymesIBA 10/2011 - 01/2011
2	Collagen Type I (Type I Collagen)IBA 01/2011 - 10/2004
2	NF-kappa B (NF-kB)IBA 10/2009 - 03/2008
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2008 - 02/2005
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 10/2008 - 10/2004
2	Angiotensin Receptors (Angiotensin II Receptor)IBA 10/2008 - 01/2004
2	Transforming Growth Factor beta1 (TGF beta 1)IBA 10/2008 - 10/2004
2	CollagenIBA 02/2005 - 10/2004
1	Amiodarone (Amiodarona)FDA LinkGeneric 08/2022
1	Tyrosine Kinase InhibitorsIBA 07/2022
1	Dasatinib (BMS 354825)FDA Link 07/2022
1	Docosahexaenoic AcidsIBA 04/2022
1	Congo RedIBA 03/2022
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2022

Therapy/Procedure

22	Percutaneous Coronary Intervention 01/2021 - 11/2009
19	Therapeutics 12/2021 - 09/2002
7	Stents 10/2020 - 02/2005
3	Transcatheter Aortic Valve Replacement 01/2017 - 04/2016
2	Thrombectomy 12/2021 - 05/2019
2	Punctures 04/2021 - 01/2016
2	Secondary Prevention 01/2020 - 01/2020
2	Ligation 12/2017 - 03/2012
1	Cardiac Resynchronization Therapy 05/2022
1	Cardiac Resynchronization Therapy Devices 05/2022
1	Catheter Ablation 01/2022